A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.06.466 ◽

2019 ◽

Vol 105 (1) ◽

pp. S43

Author(s):

J.R. Bellon ◽

Y.H. Chen ◽

R. Rees ◽

A.G. Taghian ◽

J.S. Wong ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Stage Ii ◽

Prospective Phase

Download Full-text

A phase I dose-escalation trial of radiation therapy and concurrent cisplatin for stage II and III triple-negative breast cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.03.002 ◽

2021 ◽

Author(s):

Jennifer R. Bellon ◽

Yu-Hui Chen ◽

Rebecca Rees ◽

Alphonse G. Taghian ◽

Julia S. Wong ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Dose Escalation ◽

Triple Negative ◽

Download Full-text

Abstract OT3-04-01: A phase I of olaparib with radiation therapy in patients with inflammatory, loco-regionally advanced or metastatic TNBC (triple negative breast cancer) or patient with operated TNBC with residual disease

10.1158/1538-7445.sabcs17-ot3-04-01 ◽

2018 ◽

Author(s):

YM Kirova ◽

M Ezzalfani ◽

M Rodrigues ◽

J-Y Pierga ◽

A Salomon ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Residual Disease

Download Full-text

Abstract CT040: A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

10.1158/1538-7445.sabcs18-ct040 ◽

2019 ◽

Author(s):

Hatem Soliman ◽

Deanna Hogue ◽

Hyo Han ◽

Blaise Mooney ◽

Ricardo Costa ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Talimogene Laherparepvec

Download Full-text

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Breast Cancer Research ◽

10.1186/bcr3484 ◽

2013 ◽

Vol 15 (5) ◽

Author(s):

Rebecca A Dent ◽

Geoffrey J Lindeman ◽

Mark Clemons ◽

Hans Wildiers ◽

Arlene Chan ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Parp Inhibitor ◽

Line Treatment ◽

Download Full-text

Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab

10.1158/1538-7445.sabcs15-p3-14-02 ◽

2016 ◽

Author(s):

RK Basho ◽

M Gilcrease ◽

RK Murthy ◽

T Helgason ◽

DJ Booser ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Triple Negative ◽

Mtor Pathway ◽

Proof Of Concept ◽

Mtor Inhibition

Download Full-text

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3105 ◽

2020 ◽

Author(s):

Hatem Soliman ◽

Deanna Hogue ◽

Hyo Han ◽

Blaise Mooney ◽

Ricardo Costa ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Talimogene Laherparepvec

Download Full-text

LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

Annals of Oncology ◽

10.1016/j.annonc.2021.03.213 ◽

2021 ◽

Vol 32 ◽

pp. S60

Author(s):

A. Bardia ◽

D. Juric ◽

T. Shimizu ◽

A. Tolcher ◽

R. Karim ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Antibody Drug Conjugate ◽

Preliminary Results ◽

Drug Conjugate ◽

Ongoing Phase ◽

Download Full-text

Abstract CT040: A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

10.1158/1538-7445.am2019-ct040 ◽

2019 ◽

Author(s):

Hatem Soliman ◽

Deanna Hogue ◽

Hyo Han ◽

Blaise Mooney ◽

Ricardo Costa ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative ◽

Talimogene Laherparepvec

Download Full-text

Abstract P6-18-18: Phase I trial of eribulin and everolimus in patients with metastatic triple negative breast cancer

10.1158/1538-7445.sabcs18-p6-18-18 ◽

2019 ◽

Author(s):

Y Yuan ◽

S Yost ◽

S Blanchard ◽

H Yin ◽

M Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Phase I Trial ◽

Triple Negative

Download Full-text

JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial

Annals of Translational Medicine ◽

10.21037/atm.2019.09.08 ◽

2019 ◽

Vol 7 (18) ◽

pp. 435-435 ◽

Author(s):

Li Bian ◽

Huiqiang Zhang ◽

Tao Wang ◽

Shaohua Zhang ◽

Haifeng Song ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Systemic Therapy ◽

Phase I Trial ◽

Triple Negative ◽

Breast Cancer Patients

Download Full-text